Biocept - Model NGS - Next-Gen Sequencing Lung Panel - Liquid Biopsy Biomarker

Combining Biocept’s Liquid Biopsy biomarker testing expertise with Oncomine^™ from Thermo Fisher Scientific’s next-generation sequencing and decision support resources.

Most popular related searches

biopsy biomarker

liquid biopsy

Exclusive, targeted and actionable; approximately 70% of biomarkers investigated are based on NCCN Guidelines and/or FDA approved therapies
Cost effective NGS-based solution
Turn-around-time (7-10 days upon receipt of specimen in most cases)
Specimen requirements: 8 mLs of peripheral blood in CEE-SURE^™ or EDTA Tube
Sensitivity: 96-99% (MAF ≥0.1%)
Raw data file available for further research

Biocept - Model NGS - Next-Gen Sequencing Lung Panel - Liquid Biopsy Biomarker

Product Details